Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
Company profile
Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
JOHNSON & JOHNSON ET AL
SEC CIK
Corporate docs
Subsidiaries
ABD Holding Company, Inc. • ABIOMED COMMERCIAL, LLC • ABIOMED R&D, Inc. • ABIOMED, Inc. • Acclarent, Inc. • Actelion Pharmaceuticals US, Inc. • Albany Street LLC • ALZA Corporation • Alza Land Management, Inc. • AMO Development, LLC ...
IRS number
221024240
JNJ stock data
Latest filings (excl ownership)
8-K
Other Events
17 May 24
424B2
Prospectus for primary offering
16 May 24
FWP
Free writing prospectus
14 May 24
424B5
Prospectus supplement for primary offering
14 May 24
424B5
Prospectus supplement for primary offering
13 May 24
10-Q
2024 Q1
Quarterly report
1 May 24
8-K
Results of Operations and Financial Condition
1 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
29 Apr 24
8-K/A
Johnson & Johnson Reports Q1 2024 Results
16 Apr 24
8-K
Johnson & Johnson Reports Q1 2024 Results
16 Apr 24
Transcripts
JNJ
Earnings call transcript
2024 Q1
16 Apr 24
JNJ
Earnings call transcript
2023 Q4
23 Jan 24
JNJ
Earnings call transcript
2023 Q3
17 Oct 23
JNJ
Earnings call transcript
2023 Q2
20 Jul 23
JNJ
Earnings call transcript
2023 Q1
18 Apr 23
JNJ
Earnings call transcript
2022 Q4
24 Jan 23
JNJ
Earnings call transcript
2022 Q3
18 Oct 22
JNJ
Earnings call transcript
2022 Q2
19 Jul 22
JNJ
Earnings call transcript
2022 Q1
19 Apr 22
JNJ
Earnings call transcript
2021 Q4
25 Jan 22
Latest ownership filings
13F-HR
Quarterly holdings report by institutional manager
10 May 24
4
JOHN C REED
3 May 24
4
Mary C Beckerle
29 Apr 24
4
MARILLYN A HEWSON
29 Apr 24
4
Nadja West
29 Apr 24
4
Darius Adamczyk
29 Apr 24
4
Eugene A. Woods
29 Apr 24
4
ANNE M MULCAHY
29 Apr 24
4
MARK A WEINBERGER
29 Apr 24
4
Mark B. McClellan
29 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Oct 23 | Jul 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Jan 23 | Jan 22 | Jan 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.47 bn | 25.47 bn | 25.47 bn | 25.47 bn | 25.47 bn | 25.47 bn |
Cash burn (monthly) | (no burn) | 116.00 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 183.27 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 25.29 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 218.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
51.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3302 |
Opened positions | 294 |
Closed positions | 586 |
Increased positions | 1105 |
Reduced positions | 1629 |
13F shares | Current |
---|---|
Total value | 174.14 tn |
Total shares | 1.23 bn |
Total puts | 5.14 mm |
Total calls | 4.06 mm |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 229.39 mm | $35.95 tn |
STT State Street | 132.90 mm | $20.83 tn |
MS Morgan Stanley | 41.66 mm | $6.53 tn |
Whalerock Point Partners | 35.41 mm | $5.55 bn |
JPM JPMorgan Chase & Co. | 29.75 mm | $4.66 tn |
NTRS Northern Trust | 29.73 mm | $4.66 tn |
Capital International Investors | 28.99 mm | $4.54 tn |
Wellington Management | 24.02 mm | $3.76 tn |
BK Bank Of New York Mellon | 22.23 mm | $3.48 tn |
LGEN Legal & General | 22.10 mm | $3.46 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | John C Reed | Common Stock | Payment of exercise | Dispose F | No | No | 144.59 | 10,984 | 1.59 mm | 11,577 |
1 May 24 | John C Reed | Common Stock | Option exercise | Acquire M | No | No | 0 | 22,255 | 0.00 | 22,561 |
1 May 24 | John C Reed | Restricted Share Units Common Stock | Option exercise | Dispose M | No | No | 0 | 22,255 | 0.00 | 53,510 |
25 Apr 24 | Joly Hubert | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 0 | 1,385.697 | 0.00 | 6,464.145 |
25 Apr 24 | Jennifer A Doudna | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 0 | 1,385.697 | 0.00 | 8,081.638 |
25 Apr 24 | Johnson Paula A | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 0 | 1,385.697 | 0.00 | 2,858.548 |
25 Apr 24 | Mary C Beckerle | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 0 | 1,385.697 | 0.00 | 13,643.012 |
News
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
16 May 24
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
16 May 24
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
16 May 24
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment for $850M Cash and Earnout Consideration
16 May 24
10 Health Care Stocks With Whale Alerts In Today's Session
15 May 24
Press releases
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
16 May 24
Kenvue Announces Pricing of Secondary Offering
14 May 24
Kenvue Announces Launch of Secondary Offering
13 May 24
SHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAV
9 May 24
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
9 May 24